There’s a theme developing in the 2020 outlooks Wall Street analysts covering big pharma are putting out this week: next year is looking good for the sector. In a note out Wednesday morning, Morgan Stanley’s David Risinger upgraded his view on the industry to Attractive from In-Line.
Trending:
Pharmaceutical stocks had a rough year. Here's why 2020 could be better.